0 Recommendations

Use of monoclonal antibodies to prevent sexual transmission of HIV

By Junior Bazile Moderator | 06 Aug, 2017

Hi all,
Scientist are in the process of using passive immunization, the transfer of antibodies to a non-immune individual, to provide immunological protection to HIV. What do you think of this approach?

Here's the abstract of a paper that was recently published:
Passive immunization, the transfer of antibodies to a nonimmune individual to provide immunological protection, has been used for over 100 years to prevent and treat human infectious diseases. The introduction of techniques to produce human mAbs has revolutionized the field, and a large number of human mAbs have been licensed for the treatment of cancer, autoimmune and inflammatory diseases. With the recent discovery and production of highly potent broadly neutralizing and other multifunctional antibodies to HIV, mAbs are now being considered for HIV therapy and prophylaxis. In this review, we briefly present recent advances in the anti-HIV mAb field and outline strategies for the selection, engineering and production of human mAbs, including the modification of their structure for optimized stability and function. We also describe results from nonhuman primate studies and phase 1 clinical trials that have tested the safety, tolerability, pharmacokinetics, and efficacy of mAb-based HIV prevention strategies, and discuss the future of parenteral and topical mAb administration for the prevention of HIV transmission

The full article can be accessed in the link attached to this post.
Looking forward to reading your reaction.


Attached resource:



Nyakulira Kandiwo Replied at 10:03 AM, 17 Nov 2018

An interesting read

Sachin Bhise Replied at 9:16 AM, 18 Nov 2018

Sent from RediffmailNG on Android

DIGANTA THAKURIA Replied at 12:18 PM, 18 Nov 2018

Dear Junior Bazile,

A very interesting read indeed.

I have been using few monoclonal antibodies in hematological cancers, and
if anything, expecting very few side effects in this preventive aspect too.

And if the efficacy is good, this can be life changing for a lot of people
and can help us HIV physicians address few grey areas that were otherwise

Will be keeping an eye on the developments.

Thanks for the information.


This Community is Archived.

This community is no longer active as of December 2018. Thanks to those who posted here and made this information available to others visiting the site.